These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29303083)

  • 1. Patented and Approval Scenario of Nanopharmaceuticals with Relevancy to Biomedical Application, Manufacturing Procedure and Safety Aspects.
    Agarwal V; Bajpai M; Sharma A
    Recent Pat Drug Deliv Formul; 2018; 12(1):40-52. PubMed ID: 29303083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards improved therapies using nanopharmaceuticals: recent patents on pharmaceutical nanoformulations.
    Horstkotte E; Odoerfer KI
    Recent Pat Food Nutr Agric; 2012 Dec; 4(3):220-44. PubMed ID: 23013408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patenting of nanopharmaceuticals in drug delivery: no small issue.
    du Toit LC; Pillay V; Choonara YE; Pillay S; Harilall SL
    Recent Pat Drug Deliv Formul; 2007; 1(2):131-42. PubMed ID: 19075880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics.
    Colombo S; Beck-Broichsitter M; Bøtker JP; Malmsten M; Rantanen J; Bohr A
    Adv Drug Deliv Rev; 2018 Mar; 128():115-131. PubMed ID: 29626549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals.
    Berkner S; Schwirn K; Voelker D
    Environ Toxicol Chem; 2016 Apr; 35(4):780-7. PubMed ID: 25931425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities and obstacles to the development of nanopharmaceuticals for human use.
    Nassiri Koopaei N; Abdollahi M
    Daru; 2016 Oct; 24(1):23. PubMed ID: 27716350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.
    Souto EB; Silva GF; Dias-Ferreira J; Zielinska A; Ventura F; Durazzo A; Lucarini M; Novellino E; Santini A
    Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32053962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.
    Petrovic S; Bita B; Barbinta-Patrascu ME
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges associated and approaches for successful translation of nanomedicines into commercial products.
    Agrahari V; Hiremath P
    Nanomedicine (Lond); 2017 Apr; 12(8):819-823. PubMed ID: 28338401
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals.
    Gaspar R
    Nanomedicine (Lond); 2007 Apr; 2(2):143-7. PubMed ID: 17716116
    [No Abstract]   [Full Text] [Related]  

  • 12. Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
    Rodríguez F; Caruana P; De la Fuente N; Español P; Gámez M; Balart J; Llurba E; Rovira R; Ruiz R; Martín-Lorente C; Corchero JL; Céspedes MV
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines accessible in the market for clinical interventions.
    Gadekar V; Borade Y; Kannaujia S; Rajpoot K; Anup N; Tambe V; Kalia K; Tekade RK
    J Control Release; 2021 Feb; 330():372-397. PubMed ID: 33370576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanopharmaceuticals (part 1): products on the market.
    Weissig V; Pettinger TK; Murdock N
    Int J Nanomedicine; 2014; 9():4357-73. PubMed ID: 25258527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanopharmaceutical-based regenerative medicine: a promising therapeutic strategy for spinal cord injury.
    Zhao C; Xing Z; Zhang C; Fan Y; Liu H
    J Mater Chem B; 2021 Mar; 9(10):2367-2383. PubMed ID: 33662083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in Nanomedicine: Approved and Investigational Nanodrugs.
    Ventola CL
    P T; 2017 Dec; 42(12):742-755. PubMed ID: 29234213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures.
    Ragelle H; Danhier F; Préat V; Langer R; Anderson DG
    Expert Opin Drug Deliv; 2017 Jul; 14(7):851-864. PubMed ID: 27730820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging nanopharmaceuticals.
    Bawarski WE; Chidlowsky E; Bharali DJ; Mousa SA
    Nanomedicine; 2008 Dec; 4(4):273-82. PubMed ID: 18640076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.